Dr. Lal PathLabs' board to review unaudited Q2 FY26 results and may announce the second interim dividend for shareholders.

• Board to approve standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, during the meeting.
• Possible declaration of second interim dividend for FY26 on the company’s equity shares, subject to board approval.
• The company offers diagnostic and healthcare testing services across India, focusing on disease prevention, monitoring, and treatment through advanced pathology solutions.